Wu Renzheng, Zeng Mingtang, Zhang Yuchen, He Jianping
Department of Pharmacy, West China Hospital, Sichuan University, Chengdu, China.
Division of Abdominal Tumor Multimodality Treatment, Department of Medical Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, China.
Front Oncol. 2024 Dec 18;14:1514578. doi: 10.3389/fonc.2024.1514578. eCollection 2024.
Melanoma, a highly aggressive skin cancer, poses significant challenges in treatment, particularly for advanced or metastatic cases. While immunotherapy, especially immune checkpoint inhibitors (ICIs) targeting CTLA-4 and PD-1, has transformed melanoma management, many patients experience limited responses or develop resistance, highlighting the need for new therapeutic strategies. Lymphocyte activation gene 3 (LAG-3) has emerged as a promising target in cancer immunotherapy. LAG-3 inhibitors have shown potential in restoring T cell functions and enhancing anti-tumor immunity, particularly when used in combination with existing ICIs. This review discusses the latest advancements in LAG-3 inhibition for advanced melanoma, emphasizing its role in overcoming resistance and improving patient outcomes.
黑色素瘤是一种侵袭性很强的皮肤癌，在治疗方面带来了重大挑战，尤其是对于晚期或转移性病例。虽然免疫疗法，特别是针对细胞毒性T淋巴细胞相关蛋白4（CTLA-4）和程序性死亡受体1（PD-1）的免疫检查点抑制剂（ICI），已经改变了黑色素瘤的治疗方式，但许多患者反应有限或产生耐药性，这凸显了新治疗策略的必要性。淋巴细胞激活基因3（LAG-3）已成为癌症免疫治疗中一个有前景的靶点。LAG-3抑制剂在恢复T细胞功能和增强抗肿瘤免疫力方面显示出潜力，特别是与现有的ICI联合使用时。这篇综述讨论了晚期黑色素瘤LAG-3抑制的最新进展，强调了其在克服耐药性和改善患者预后方面的作用。
